SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function
Phase of Trial: Phase II
Latest Information Update: 01 May 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms SAFE-HEaRt
- 10 Jun 2017 Biomarkers information updated
- 01 May 2017 Trial design published in the Oncologist.
- 08 Feb 2015 Planned number of patients changed from 33 to 30, as reported by ClinicalTrials.gov.